$15.00
+0.50 (+3.45%)
Open$14.45
Previous Close$14.50
Day High$15.01
Day Low$14.45
52W High$15.79
52W Low$7.87
Volume—
Avg Volume127.8K
Market Cap191.36M
P/E Ratio—
EPS$-0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+59.9% upside
Current
$15.00
$15.00
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 105.44M | 117.52M | 23.45M |
| Net Income | -10,168,490 | -10,200,224 | 5.38M |
| Profit Margin | -9.6% | -9.2% | 22.9% |
| EBITDA | -5,308,037 | -5,620,413 | 8.65M |
| Free Cash Flow | — | — | 4.59M |
| Rev Growth | -10.3% | -10.3% | -4.1% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |